Art. -Nr.: HY-136642

Fluocinolone

Kundenbewertung

Based on 1 Customer Validation

Fluocinolone is a potent steroid with highly selective glucocorticoid receptor agonist activity. Fluocinolone stabilizes the blood-retinal barrier by enhancing endothelial tight junctions, inhibiting the VEGF pathway and inflammatory factors. Fluocinolone has high lipophilicity, enabling long-term sustained release in the vitreous. Fluocinolone is used in research related to dermatological diseases, diabetic macular edema, uveitis and oral lichen planus.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.48%
CAS. Nr.: 807-38-5
Formel: C₂₁H₂₆F₂O₆
Molecular Weight:412.42

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Fluocinolone Chemical Structure

CAS. Nr.: 807-38-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

Fluocinolone derivative Fluocinolone acetonide (HY-B0415) enhances endothelial tight junction activity and suppresses VEGF expression and inflammatory cytokine signaling in retinal endothelial cells^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Fluocinolone derivative Fluocinolone acetonide (HY-B0415) (0.1-1.0 mg/kg; s.c.; once daily; 3-7 days) reduces serum and adrenal corticosterone levels in rats^[1].
Fluocinolone derivative Fluocinolone acetonide (HY-B0415) (sustained device; 2 mg/15 mg; intravitreal implantation; 5-19 months) suppresses ocular inflammation and improves visual acuity in severe uveitis models^[3].
Fluocinolone derivative Fluocinolone acetonide (HY-B0415) (0.2 μg/day; intravitreal implant; sustained for 36 months) maintains stable intraocular drug levels with undetectable systemic exposure in rabbits^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 807-38-5
Appearance Solid
Molecular Weight 412.42
Formel C₂₁H₂₆F₂O₆
Color White to off-white
SMILES

F[C@]([C@](C1=CC2=O)(C=C2)C)([C@H](C3)O)[C@](C[C@@H]1F)([H])[C@@](C[C@H]4O)([H])[C@]3([C@](O)4C(CO)=O)C
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (242.47 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4247 mL

12.1236 mL

24.2471 mL

5 mM

0.4849 mL

2.4247 mL

4.8494 mL

10 mM

0.2425 mL

1.2124 mL

2.4247 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (12.12 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 5 mg/mL (12.12 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (12.12 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Aizawa Y, et al. Effects of difluprednate on adrenal cortex and gonadal functions. Folia Pharmacologica Japonica, 1984, 84: 553-561.

[2]. Buajeeb W, et al. Efficacy of fluocinolone acetonide gel in the treatment of oral lichen planus. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, 2000, 89(1): 42-45.

[3]. Jaffe GJ, et al. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000;107(11):2024-2033. [Content Brief]

[4]. Veritti D, et al. Fluocinolone acetonide for the treatment of diabetic macular edema. Expert Opinion on Pharmacotherapy, 2017, 18(14): 1507-1516.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4247 mL	12.1236 mL	24.2471 mL	60.6178 mL
	5 mM	0.4849 mL	2.4247 mL	4.8494 mL	12.1236 mL
	10 mM	0.2425 mL	1.2124 mL	2.4247 mL	6.0618 mL
	15 mM	0.1616 mL	0.8082 mL	1.6165 mL	4.0412 mL
	20 mM	0.1212 mL	0.6062 mL	1.2124 mL	3.0309 mL
	25 mM	0.0970 mL	0.4849 mL	0.9699 mL	2.4247 mL
	30 mM	0.0808 mL	0.4041 mL	0.8082 mL	2.0206 mL
	40 mM	0.0606 mL	0.3031 mL	0.6062 mL	1.5154 mL
	50 mM	0.0485 mL	0.2425 mL	0.4849 mL	1.2124 mL
	60 mM	0.0404 mL	0.2021 mL	0.4041 mL	1.0103 mL
	80 mM	0.0303 mL	0.1515 mL	0.3031 mL	0.7577 mL
	100 mM	0.0242 mL	0.1212 mL	0.2425 mL	0.6062 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Fluocinolone

Immunology/Inflammation Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Rare Diseases Drug Library

Human Metabolite Library

Nuclear Receptor Compound Library

Pain-Related Compound Library

Highly Selective Activators Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Fluocinolone

Immunology/Inflammation Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Rare Diseases Drug Library

Human Metabolite Library

Nuclear Receptor Compound Library

Pain-Related Compound Library

Highly Selective Activators Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Fluocinolone Related Classifications

HY-136642 Related Classifications